The firm announced a 14 percent drop year-over-year in fourth quarter revenues and plans to reduce personnel and other costs to support development of a precision drug it has licensed.
The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.
The company believes that the reduction in staff and marketing costs for its testing services will reduce its annual pre-tax expenses by about $4 million.
The companies will co-develop kits, which Trovagene will distribute globally, to analyze ctDNA from blood or urine using next-generation sequencing platforms.
The increase was driven by higher demand for its diagnostic services related to its line of blood- and urine-based assays for the detection of cancer-associated genetic mutations.
The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.
The in-network agreement gives the health plan's 8 million members access to Trovagene's full menu of liquid biopsy tests.
Trovagene posted Q2 revenues of $104,000 compared to $50,000 in Q2 2015, missing the Wall St. estimate of $270,000.
The company continues to build evidence for the added sensitivity offered by its urine- and blood-based liquid biopsy approach in an effort to engage clinicians.
The collaboration will develop a clinical framework for deploying the Trovera liquid biopsy tests and general best practices for urine-based liquid biopsies.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.